Horizon Pharma plc, of Dublin, reported its fourth-quarter net sales were $355.5 million, an increase of 30 percent, driven by continued strong growth of the company's orphan and rheumatology segment. For the year, Krystexxa (pegloticase) net sales were $258.9 million, representing a 65 percent year-over-year increase.